Pages that link to "Q47961549"
Jump to navigation
Jump to search
The following pages link to Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes (Q47961549):
Displaying 50 items.
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (Q27692687) (← links)
- CYP2C9 allelic variants: ethnic distribution and functional significance (Q28212029) (← links)
- A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement (Q28217697) (← links)
- Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol (Q28288315) (← links)
- Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin (Q28343618) (← links)
- A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9 (Q28468645) (← links)
- Influence of sampling on the determination of warfarin and warfarin alcohols in oral fluid (Q28542544) (← links)
- Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing (Q32049910) (← links)
- Warfarin-acetaminophen drug interaction revisited (Q33747163) (← links)
- Cytochrome P450-mediated drug interactions. (Q33837443) (← links)
- Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children (Q33998916) (← links)
- A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients (Q34026245) (← links)
- Pharmacogenetics of warfarin elimination and its clinical implications (Q34347249) (← links)
- The future prospects of pharmacogenetics in oral anticoagulation therapy (Q34530230) (← links)
- Pharmacogenomics in anticoagulant drug development (Q35000929) (← links)
- Implications of pharmacogenetics for individualizing drug treatment and for study design (Q35102211) (← links)
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin (Q35204081) (← links)
- Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans (Q35612111) (← links)
- Challenges of implementing pharmacogenetics in the critical care environment (Q35621396) (← links)
- Association of warfarin dose with genes involved in its action and metabolism (Q35633802) (← links)
- Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes (Q35718630) (← links)
- Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers (Q35753607) (← links)
- Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population (Q35803786) (← links)
- Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes (Q35873687) (← links)
- Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms (Q35876954) (← links)
- Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes (Q36087965) (← links)
- The pharmacogenetics of coumarin therapy. (Q36192806) (← links)
- The future of warfarin pharmacogenetics in under-represented minority groups (Q36294461) (← links)
- Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? (Q36380430) (← links)
- Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. (Q36387998) (← links)
- Role of cytochrome P450 genotype in the steps toward personalized drug therapy (Q36441521) (← links)
- Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples (Q36487475) (← links)
- Pharmacogenetics of chronic cardiovascular drugs: applications and implications (Q36543128) (← links)
- Pharmacogenetics of warfarin: current status and future challenges (Q36597343) (← links)
- Pharmacogenetics of target genes across the warfarin pharmacological pathway (Q36656419) (← links)
- Role of pharmacogenomics in the management of traditional and novel oral anticoagulants (Q36848449) (← links)
- Pharmacogenetics and cardiovascular disease--implications for personalized medicine (Q36974672) (← links)
- Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study (Q37138272) (← links)
- Pharmacogenetics of oral anticoagulants: a basis for dose individualization (Q37242614) (← links)
- Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism (Q37429282) (← links)
- Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know (Q37863679) (← links)
- Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review (Q38001074) (← links)
- Cytochrome P450 and ischemic heart disease: current concepts and future directions (Q38166022) (← links)
- Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. (Q38384338) (← links)
- CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites (Q38830008) (← links)
- CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. (Q40174813) (← links)
- Voriconazole potentiates warfarin‐induced prothrombin time prolongation (Q42029509) (← links)
- Benzbromarone Pharmacokinetics and Pharmacodynamics in Différent Cytochrome P450 2C9 Genotypes (Q42852451) (← links)
- Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response (Q43114229) (← links)
- CYP2C19 genotype-based (R)-warfarin disposition assessment - some views on data analysis (Q43154053) (← links)